Endocytosis, trafficking and exocytosis of intact full-length Botulinum neurotoxin type A in cultured rat neurons by Solabre Valois, Luis et al.
                          Solabre Valois, L., Wilkinson, K. A., Nakamura, Y., & Henley, J. M.
(2020). Endocytosis, trafficking and exocytosis of intact full-length
Botulinum neurotoxin type A in cultured rat neurons. NeuroToxicology,
78 (2020), 80-87. https://doi.org/10.1016/j.neuro.2020.02.009
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1016/j.neuro.2020.02.009
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Elsevier at
https://doi.org/10.1016/j.neuro.2020.02.009 . Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/user-guides/explore-bristol-research/ebr-terms/
Contents lists available at ScienceDirect
Neurotoxicology
journal homepage: www.elsevier.com/locate/neuro
Full Length Article
Endocytosis, trafficking and exocytosis of intact full-length botulinum
neurotoxin type a in cultured rat neurons
Luis Solabre Valois, Kevin A. Wilkinson, Yasuko Nakamura, Jeremy M. Henley*
School of Biochemistry, Centre for Synaptic Plasticity, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK
A R T I C L E I N F O
Keywords:
Neuron
Botulinum neurotoxin type A
BoNT/A
Degradation
Endocytosis
A B S T R A C T
Botulinum toxin A (BoNT/A) is a potent neurotoxin that acts primarily by silencing synaptic transmission by
blocking neurotransmitter release. BoNT/A comprises a light chain (LC/A) intracellular protease and a heavy
chain (HC/A) composed of a receptor binding domain (HCC/A) and a translocation domain (HCN/A) that
mediates cell entry. Following entry into the neuron, the disulphide bond linking the two peptide chains is
reduced to release the LC/A. To gain better insight into the trafficking and fate of BoNT/A before dissociation we
have used a catalytically inactive, non-toxic full-length BoNT/A(0) mutant. Our data confirm that BoNT/A(0)
enters cortical neurons both in an activity-dependent manner and via a pathway dependent on fibroblast growth
factor receptor 3 (Fgfr3) signalling. We demonstrate that both dynamin-dependent endocytosis and lipid rafts
are involved in BoNT/A internalisation and that full-length BoNT/A(0) traffics to early endosomes. Furthermore,
while a proportion of BoNT/A remains stable in neurons for 3 days, BoNT/A degradation is primarily mediated
by the proteasome. Finally, we demonstrate that a fraction of the endocytosed full-length BoNT/A(0) is capable
of exiting the cell to intoxicate other neurons. Together, our data shed new light on the entry routes, trafficking
and degradation of BoNT/A, and confirm that trafficking properties previously described for the isolated HCC/A
receptor binding domain of are also applicable to the intact, full-length toxin.
1. Introduction
The clostridial neurotoxin (CNT) family of proteins includes several
serotypes of BoNTs and tetanus neurotoxin (TeNT) (Arnon et al., 2001;
Montecucco and Schiavo, 1994). CNTs comprise a ∼50 kDa Light
Chain (LC) and a∼100 kDa Heavy Chain (HC) connected by a disulfide
bond (Lacy et al., 1998; Montal, 2010; Montecucco and Schiavo, 1994).
The LC is a metalloprotease that cleaves proteins of the Soluble N-
ethylmaleimide-sensitive factor Attachment Protein Receptor (SNARE)
complex, blocking synaptic vesicle exocytosis (Schiavo et al., 1994).
The HC is further divided into two functional domains: the C-terminal
receptor-binding domain (HCC) mainly responsible for endocytosis and
trafficking, and an N-terminal pore-forming domain (HCN), which al-
lows the translocation of the LC into the cytosol once it has been en-
docytosed (Dong et al., 2018).
Intoxication by a CNT can be summarised in three steps: i) HCC
binds to the cell membrane and is internalised into an endocytic com-
partment; ii) HCN domain forms a channel in the endocytosed vesicle
membrane; iii) LC translocates through HCN to the cytosol, separates
from the HC and targets SNARE proteins, blocking synaptic vesicle
release (Dong et al., 2018).
This functional separation of BoNT/A domains has generated va-
luable information on the processes underlying BoNT/A action. For
example, BoNT/A trafficking has been extensively investigated using
the isolated receptor-binding domain (HCC/A). HCC/A binds to receptor
proteins and gangliosides at the neuronal surface to facilitate its in-
corporation into several different pools of synaptic vesicles (Harper
et al., 2016; Pellett et al., 2015; Restani et al., 2012b). HCC/A then
enters the endocytic pathway where most progresses on to autopha-
gosomes but a fraction remains stable in early endosomes (Colasante
et al., 2013; Couesnon et al., 2009; Harper et al., 2011). From early
endosomes it can be retrogradely trafficked, exocytosed and taken up
by surrounding cells (Bomba-Warczak et al., 2016; Restani et al.,
2012b; Wang et al., 2016). In addition, a proportion of HCC/A mole-
cules also traffic to lysosomes for degradation (Harper et al., 2011;
Wang et al., 2015a, 2015b).
Notwithstanding this progress using the specific HCC/A domain as a
tool, it remains unclear if it faithfully reports the fate of full-length
BoNT/A. This issue is highlighted by the observation that the corre-
sponding domain of TeNT, HCC/T, is trafficked differently to full-length
TeNT and isolated fragments of the toxin (Blum et al., 2012; Ovsepian
et al., 2015), and other groups have reported that both HCN/A and LC/
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A are involved in trafficking (Ayyar et al., 2015; Montecucco et al.,
1988).
To investigate the trafficking and fate of full-length BoNT/A prior to
dissociation we have used BoNT/A(0), a catalytically inactive and non-
toxic full-length point mutant, to follow the endocytosis, trafficking and
degradation of the toxin. Our rationale is that the trafficking of this
point mutated full-length toxin protein should be more informative
than looking at individual toxin subunits or fragments, which have been
used previously. Furthermore, the fact that is safe to use and relatively
easy to produce makes it an amenable tool for labs that do not have
high-level biosecurity and containment facilities or the licencing to
produce and investigate the fully active toxin.
Our data show that BoNT/A(0) enters neurons via activity-depen-
dent and Fgfr3-mediated routes that involve both dynamin and lipid
rafts. Once internalised, BoNT/A(0) traffics through early endosomes
but escapes lysosomal degradation, being largely degraded by the
proteasome. However, a fraction of internalised BoNT/A(0) is stable for
at least 3 days in neurons. Finally, we demonstrate that a fraction of
intact BoNT/A(0) can be exocytosed from neurons and enter sur-
rounding cells.
2. Materials and methods
2.1. Primary neuronal cultures
Dissociated hippocampal and cortical neuronal cultures were pre-
pared as previously described (Carmichael et al., 2018; Martin and
Henley, 2004). Briefly, pregnant Wistar rats were sacrificed by schedule
1 lethal anaesthesia, following procedures in full compliance with
ARRIVE guidelines and the U.K. Animals Scientific Procedures Act,
1986. Neurons were dissected from E18 Wistar rat pups followed by
trypsin dissociation and cultured for up to 2 weeks. For the first 24 h,
cells were grown in plating media: Neurobasal media (Gibco) supple-
mented with 5% horse serum (Sigma), B27 (1x, Gibco), P/S (100 units
penicillin and 0.1 mg/ml streptomycin; ThermoScientific) and 5 mM
Glutamax (Gibco). After 24 h, plating media was replaced with feeding
media (same composition as plating medium but containing 2 mM
Glutamax and lacking horse serum). For biochemistry experiments,
cells were plated at a density of 500,000 per 35 mm well and 250,000
per coverslip for imaging experiments. Animal care and procedures
were carried out in accordance with UK Home Office and University of
Bristol guidelines.
2.2. Production of recombinant BoNT/A(0)
BoNT/A(0), containing two point mutations, E224Q/H227Y, that
render it catalytically inactive (Kukreja et al., 2007; Zhou et al., 1995),
was supplied by Ipsen as a single chain polypeptide using their standard
protocols. The amino acid sequence of BoNT/A(0) is shown in Sup-
plementary Fig. 1.
2.3. Treatments
Cultures were exposed to 25 nM of heterodimeric BoNT/A(0) for 10
min unless indicated otherwise and all incubations were done at 37 °C.
The IC50 for BoNT/A cleavage of SNAP-25 is in the pM range but BoNT/
A(0) reaches a binding/internalisation plateau at ∼25 nM (Vazquez-
Cintron et al., 2014). Thus, to enable immuno-detection of the toxin it is
standard in the field to use nM concentrations (Harper et al., 2011,
2016; Restani et al., 2012b; Wang et al., 2015a, 2015b).
Where indicated, TTX (2 μM) was applied 18 h before BoNT/A(0) to
suppress synaptic transmission. Bicucculine (1 μM) was applied 1 h
before BoNT/A(0) to block inhibitory GABAA receptors and enhance
synaptic transmission.
The Fgfr3 inhibitor SU5402 (20 μM), the dynamin inhibitor
MiTMAB (25 μM), the cholesterol-extracting agent methyl-β-
cyclodextrin (MCD; 1 mM), the lysosomal degradation blocker leu-
peptin (30 μM), and proteasomal degradation blocker MG132 (5 μM)
were diluted to working concentrations in feeding medium.
For pulse-chase experiments, neurons were treated for 10 min with
BoNT/A(0), washed and immediately fixed (designated as 0 min) or
incubated for a further 10 min or 60 min prior to fixing. A further
control not exposed to BoNT/A(0) was also included in these experi-
ments. Neurons were then immunolabelled with antibodies against
BoNT/A and the early endosome marker EEA1.
For stability studies, cells were incubated in pre-warmed feeding
medium with BoNTA(0) for 10 min and were then washed three times
with PBS. Their media was replaced, and cells were incubated for the
times indicated.
For degradation studies, cells were incubated in medium containing
the desired proteolysis inhibitors for 30 min before applying BoNT/
A(0). After the 30 min the inhibitor media was removed and pre-
warmed feeding media containing both the toxin and the relevant
proteolysis inhibitor at the concentration specified was applied to the
corresponding cultures. Cultures were exposed to BoNT/A(0) for 10
min. Then, the BoNT/A(0)-containing medium was removed, cells
washed and media with the respective proteolysis inhibitors was re-
applied and left for 18 h in the incubator.
2.4. SDS-PAGE and western blotting
Treated cells were washed thoroughly with 0.1 M glycine, 0.1 M
HCl, and then with PBS before lysing in SDS-PAGE loading buffer.
Proteins were separated by SDS-PAGE under non-reducing conditions to
preserve the integrity of the disulfide bond connecting LC and HC and
transferred to PVDF membrane for western blotting. Membranes were
blocked in 5% (w/v) non-fat milk powder in PBS-T. Antibodies were
diluted 1:10000 (GAPDH from Abcam, Cat. No. ab8245) and 1:600
(BoNT/A from Ipsen). Western blots were imaged using X-ray films in a
Fig. 1. Modulation of neuronal activity regulates BoNT/A(0) uptake into cor-
tical neurons.
A) Representative western blots of full-length BoNT/A in DIV14-17 cortical
neurons pre-treated for 1 h with vehicle (0.1 % DMSO), 1 h with 1 μM bicu-
culline or 18 h with 2 μM TTX followed by 25 nM BoNT/A(0) for 10 min.
GAPDH was used as a loading control.
B) Quantification of the western blot results. Mean values± SEM analysed
using ANOVA followed by Tukey post hoc test, *p< 0.05, **p< 0.01. N = 3.
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dark room using developer and fixer solutions. The blots were then
scanned and quantified by densitometry using FIJI (ImageJ studio).
Because we needed to use the minimal dose possible for in vitro ex-
periments, combined with the relatively short incubation times, we
worked at the limits of detection. Thus, although in some examples a
higher molecular weight band is observed, in all cases the ∼150 kDa
BoNT/A(0) band was used for densitometric quantification, which was
consistently reproducible between experiments. In all cases, intensities
for BoNT/A(0) signal were normalised to the GAPDH signal from the
same sample.
2.5. Immunofluorescence
Cells were washed with phosphate buffered saline (PBS) and fixed
with pre-warmed 4% paraformaldehyde (PFA) for 10 min at room
temperature. Coverslips were incubated with PBS with 3% (w/v) bo-
vine serum albumin (BSA) and 0.1 % Triton X-100 for 20 min at room
temperature to block and permeabilise neurons. Antibodies were mixed
with PBS containing 3% (w/v) BSA to their appropriate working con-
centrations. Custom-made polyclonal anti-BoNT/A antibodies targeting
the full-length toxin (Eurogentec) were diluted at 1:500, EEA1 anti-
bodies (BD Biosciences, Cat. No. 610457) were diluted 1:200. These
were incubated at 4 °C overnight. Coverslips were then washed and
incubated with secondary antibodies (Jackson ImmunoResearch) in
PBS with 3% (w/v) BSA for 1 h at room temperature. Coverslips were
washed and mounted onto microscope slides using Fluoromount-G
(Thermo Fischer Scientific, Cat. No 00-4959-52). A Leica SP5-AOBS
confocal laser scanning microscope was used for confocal imaging.
2.6. Statistical analysis
All data are presented as mean± SEM. Statistical significance was
determined by One-way ANOVA followed by Tukey post hoc test or
Student’s t-test, as indicated in the figure legends, using Graphpad
Prism software. P< 0.05 was considered statistically significant;
*p< 0.05, **p<0.01. The stated N number refers to the number of
independent neuronal cultures used for each experiment.
3. Results
3.1. Synaptic activity modulates BoNT/A(0) entry into neurons
We first confirmed the uptake of BoNT/A(0) by our cultures, and
our ability to detect it, by applying BoNT/A(0) to cortical neurons for
10 min followed by western blotting with an anti-BoNT/A antibody.
Western blots confirmed that 150 kDa full-length toxin immunoreactive
bands were present only in treated neurons (Fig. 1A, control lanes).
We then determined whether full-length BoNT/A(0) internalisation
was activity-dependent by treating neuronal cultures with the Na+-
channel blocker tetrodotoxin (TTX), which prevents action potentials
and suppresses synaptic activity (Bane et al., 2014), or with the GABAA
receptor (GABAAR) antagonist bicuculline (Bic) which, by inhibiting
inhibitory synapses, increases the overall activity of the network (Olsen,
2018). Neurons were pre-treated with either vehicle (dimethyl sulph-
oxide, DMSO), TTX or Bic as specified before treatment with 25 nM
BoNT/A(0) for 10 min prior to lysis. Toxin uptake was assessed by
western blotting.
Densitometry of the western blots showed that BoNT/A(0) uptake
was 181.8± 11.7 % in Bic-treated neurons when compared to the
DMSO control (p** < 0.01), while uptake in TTX-treated neurons was
reduced to 47.5±13.2 % of control (p** < 0.01; Fig. 1A,B). These
data confirm that a substantial proportion of BoNT/A(0) is internalised
in a neuronal activity-dependent manner. However, we also observed
that TTX treatment did not completely block toxin uptake, raising the
possibility of other potential routes of entry.
3.2. A proportion of BoNT/A(0) internalisation requires Fgfr3 signalling
Fibroblast growth factor receptor 3 (Fgfr3) is a tyrosine kinase re-
ceptor that has been reported to bind to, and be activated by, HCC/A in
neuroblastoma cells (Jacky et al., 2013). To determine whether Fgfr3
contributes to BoNT/A(0) uptake in primary neurons, we used SU5402,
which inhibits Fgfr3 phosphorylation, down-stream signalling and in-
ternalisation (Lamont et al., 2011). In cortical cultures pre-treated with
SU5402 for 1 h and then incubated with 25 nM BoNT/A(0) for 10 min,
BoNT/A(0) uptake was significantly reduced compared to control
(58.8±11.9 %; p*< 0.05; Fig. 2). These data suggest that, in addition
to synaptic vesicle-mediated entry, a proportion of full-length BoNT/A
depends on Fgfr3 signalling to enter neurons.
3.3. BoNT/A(0) uses dynamin-dependent endocytosis and lipid rafts to
enter neurons
We next investigated the mechanisms of BoNT/A(0) internalisation.
To do this, we used myristyl-trimethyl-ammonium bromide (MiTMAB),
a dynamin I and dynamin II inhibitor that competitively interferes with
the ability of dynamin to bind phospholipids and prevents receptor-
mediated endocytosis (Quan et al., 2007). We also examined the effects
of methyl-β-cyclodextrin (MβCD), a complexing agent that depletes
cholesterol from membranes, specifically disrupting lipid rafts while
leaving other endocytic mechanisms unaffected at the concentrations
used (Mahammad and Parmryd, 2015; Rodal et al., 1999).
Cells were pre-treated with endocytosis inhibitors for 30 min and
exposed to BoNT/A(0) for 10 min. Both inhibitors caused a significant
Fig. 2. Blocking Fgfr3 activity significantly decreases BoNT/A(0) uptake into
cortical neurons.
A) Representative western blot of samples from DIV14-17 cortical neurons pre-
treated for 1 h with vehicle (0.1 % DMSO) or 20 μM SU5402 before incubation
for 10 min with 25 nM BoNT/A(0) in the presence of this compound, plus non-
treated controls. Membranes were probed with anti-BoNT/A and anti-GAPDH
antibodies.
B) Quantification of the results, represented as mean values± SEM. Student’s t-
test, *p< 0.05. N = 3.
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decrease in BoNT/A(0) endocytosis (Fig. 3). In MiTMAB-treated neu-
rons, internalisation of BoNT/A(0) was reduced to 57.2±12.2 % of the
control (p* < 0.05), whereas MβCD reduced BoNT/A endocytosis to
13.6±10.9 % (p**<0.01). These data suggest that BoNT/A(0) enters
neurons via both dynamin-dependent and dynamin-independent en-
docytosis.
3.4. BoNT/A(0) traffic through early endosomes in neurons is limited
To investigate the progression of BoNT/A(0) traffic into the en-
dosomal pathway we used a pulse-chase protocol followed by staining
for internalised BoNT/A(0) and the early endosomal marker EEA1.
In neurons fixed immediately after being treated with BoNT/A(0)
for 10 min (t = 0) the Manders’ coefficient of BoNT/A(0) co-localisa-
tion with EEA1 was M = 0.591± 0.112, indicating positive but in-
complete trafficking through early endosomes (Fig. 4). Values for the
later time points were normalised to this value. In cells fixed 10 min
after the end of the 10 min BoNT/A(0) incubation period co-localisation
was reduced to 42.6± 6.8 % of t = 0 (**p<0.01). This fraction re-
mained relatively constant, with a value of 57.8± 3.8 % after 60 min
(**p< 0.01). These data indicate that BoNT/A(0) very rapidly traffics
into early endosomes and ∼50 % exits within 10 min. However, co-
localisation levels remain stable 1 h after treatment.
3.5. Heterodimeric BoNT/A(0) is degraded to a stable level
It has been reported that LC/A is stable in neuronal cytoplasm for
prolonged periods (Tsai et al., 2017), but to determine the time course
of full-length BoNT/A(0) degradation, we treated neurons for 10 min
with BoNT/A(0) and then washed and returned to conditioned media
for 0 (lysed immediately), 1, 2 or 3 days. Western blot analyses with the
polyclonal antibody, which recognises both full-length ∼ 150 kDa
BoNT/A and the ∼100 kDa HC/A fragment indicated that after 1 day,
28.0±13.3 % of the originally internalised BoNT/A(0) was present
inside the cells (**p<0.01), and this amount remained constant 3 days
after treatment (Fig. 5A,B; 28.3±10.9 % after 2 days, 20.1±8.3 %
after 3 days, **p<0.01 in both cases). Since no∼100 kDa HC/A band
was detected in these cells, these data suggest that if the full-length
BoNT/A is cleaved the HC/A fragment is degraded. Thus, although
most full-length BoNT/A(0) is degraded (either before or after cleavage
into the HC/A and LC/A fragments) within 24 h, ∼30 % of the en-
docytosed full-length BoNT/A(0) remains intact and is stable for at least
3 days.
3.6. BoNT/A(0) is degraded by the proteasome and not the lysosome
To investigate how heterodimeric BoNT/A(0) is degraded in neu-
rons, we pre-treated cortical neurons with the lysosomal inhibitor
leupeptin, the proteasomal inhibitor MG132, or both, for 30 min before
applying 25 nM BoNT/A(0) for 10 min. Neurons were then washed and
incubated for a further 18 h in the continued presence of the inhibitors.
A positive control with cells treated for 10 min with 25 nM BoNT/A(0)
and DMSO was included to assess the levels of protein before de-
gradation.
In the absence of leupeptin or MG132 25.5± 3.0 % of endocytosed
∼150 kDa BoNT/A(0) remained intact after 18 h incubation compared
to the control (p** < 0.01; Fig. 5C,D). Similarly, in leupeptin-treated
neurons 28.6± 6.3 % of the original BoNT/A(0) remained after 18 h
(p< 0.01), suggesting full-length BoNT/A(0) is not subject to lyso-
somal degradation. In contrast, MG132, alone, or in combination with
leupeptin, effectively prevented full-length BoNT/A(0) degradation,
suggesting that BoNT/A(0), like Fgfr3 (Jacky et al., 2013), is primarily
degraded via the proteasome.
3.7. Intact BoNT/A(0) can be exocytosed to enter surrounding neurons
We next investigated the fate of non-dissociated, non-degraded
BoNT/A(0). DIV14-17 cortical neurons were treated with 25 nM BoNT/
A(0) for 18 h. Following this incubation period, the neurons were wa-
shed and medium was replaced with fresh feeding medium and the cells
incubated for further 24 h. The conditioned medium from the washed
previously intoxicated cells was then removed and applied to fresh
neurons that had not been previously exposed to BoNT/A(0). These
neurons were incubated in the conditioned media for 24 h. As a ne-
gative control, neurons from the same dissection were untreated and
kept in the same incubator for 66 h. A positive intoxication control was
that another batch of previously untreated neurons from the same
dissection were exposed 25 nM BoNT/A(0) for 10 min at the end of the
experiment. No gross changes in neuronal morphology were observed
under any condition. Neurons from all conditions were extensively
washed and lysed for western blotting at the same time. As shown in
Fig. 6, neurons exposed to conditioned media for 24 h contain BoNT/
A(0) similar to the positive control neurons which were exposed to 25
nM BoNT/A(0) for 10 min. These results are consistent with intact
BoNT/A(0) being released from neurons after endocytosis and entering
fresh, previously non-intoxicated neurons.
4. Discussion
4.1. BoNT/A(0) enters neurons via activity- and Fgfr3-dependent
mechanisms
We show that enhancing neuronal network activity increases,
whereas blocking neuronal activity reduces, BoNT/A(0) endocytosis
into neurons. These results confirm that BoNT/A(0) enters cortical
neurons via activity-dependent pathways consistent with a primary
route for internalisation via synaptic vesicles (Colasante et al., 2013;
Fig. 3. Methyl-β-cyclodextrin and MiTMAB inhibit BoNT/A(0) uptake.
A) Representative western blot of samples from DIV14-17 cortical neurons pre-
treated for 30 min with vehicle (0.1 % DMSO), 25 μM MiTMAB or 1 mM me-
thyl-β-cyclodextrin before incubation for 10 min with 25 nM BoNT/A(0) in the
presence of these compounds, plus non-treated controls. Membranes were
probed with anti-BoNT/A and anti-GAPDH antibodies.
B) Quantification of the results, represented as mean values± SEM. ANOVA
followed by Tukey post hoc test, *p< 0.05, **p<0.01. N = 3.
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Kristensson and Olsson, 1978). Interestingly, however, the initial
binding of BoNT/A to gangliosides in the cell membrane is independent
of neuronal activity (Simpson, 1980). Furthermore, in our experiments,
in which neurons were thoroughly washed to exclude the possibility of
a signal from surface bound but not internalised BoNT/A(0), TTX
blockade did not completely prevent BoNT/A(0) uptake, indicating
additional routes of entry. These findings raise the possibility of alter-
native routes for BoNT/A(0) entry independent of synaptic vesicles, or
that in the presence of TTX there is a basal level of constitutive synaptic
vesicle endocytosis. Although challenging, further work using specific
inhibitors of synaptic vesicle uptake, to determine the exact contribu-
tion of the synaptic vesicle cycle to full-length toxin internalisation,
would undoubtedly benefit the field.
In clonal cells, HCC/A has been reported to act as a ligand for Fgfr3
(Jacky et al., 2013), which undergoes dynamin-independent en-
docytosis (Haugsten et al., 2011). Here we show that the Fgfr3 blocker
SU5402 reduces BoNT/A(0) endocytosis in neurons, which is suppor-
tive of a role for Fgfr3 in BoNT/A(0) internalisation in neurons.
Inhibition of dynamin-dependent endocytosis by MiTMAB also im-
paired BoNT/A(0) endocytosis. However, we cannot exclude that, ra-
ther than being due to direct inhibition of dynamin-dependent vesicle
endocytosis (Bartolome-Martin et al., 2012), these effects could be
explained by alternative routes exploited by BoNT/A(0) that were in-
directly affected by MiTMAB. Depletion of membrane cholesterol with
the cyclodextrin MβCD also dramatically reduced BoNT/A(0) uptake in
our neurons, suggesting a role for lipid rafts in toxin internalisation.
Indeed, it has been reported that HCC/A binds to lipid rafts in neurons
(Herreros et al., 2001) and that in motor neuron-like NG108-15 cells,
MβCD reduces HCC/A binding to the cell membrane (Couesnon et al.,
2009). Furthermore, in differentiated PC-12 cells and spinal cord motor
neurons, the related TeNT protein uses lipid rafts to enter cells
(Deinhardt et al., 2006; Herreros et al., 2001; Munro et al., 2001), al-
though BoNT/A trafficking differs from that of TeNT (Cai et al., 2017;
Lawrence et al., 2012; Wang, F. et al., 2015). In contrast, however,
other studies have suggested that MβCD can potentiate BoNT/A in-
toxication. For example, neonatal mice, which are resistant to BoNT/A,
can be sensitised to intoxication using MβCD (Thyagarajan et al., 2017).
Furthermore, BoNT/A activity can be enhanced by MβCD in un-
differentiated Neuro2A cells (Petro et al., 2006). While the exact rea-
sons for these differences in effect of MβCD remain unclear, it is pos-
sible that they may reflect differences in the lipid composition of
different neuronal preparations.
Fig. 4. BoNT/A(0) traffics through early en-
dosomes.
A) Representative images of DIV14-17 hippo-
campal neurons treated with 25 nM BoNT/
A(0) for 10 min. After toxin exposure, cells
were washed and internalised toxin allowed to
traffic for 0 min, 10 min or 1 h. Cells were
treated at different time points and fixed at the
same time. Staining corresponds to EEA1 (red)
and BoNT/A(0) (green) and DAPI (blue). Scale
bars are 1 μm. The lower 3 rows of panels show
enlargements of the boxed area in the top pa-
nels for BoNT/A(0) (green), EEA1 (red) and
colocalization (yellow), respectively.
B) Quantification of the results, represented as
mean values± SEM. Colocalisation between
BoNT/A(0) and EEA1 measured using
Manders’ coefficient and normalised to the
value at time 0. ANOVA followed by Tukey post
hoc test, **p< 0.01. N = 3.
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4.2. BoNT/A(0) enters the endocytic pathway in neurons
BoNT/A can enter neurons via synaptic vesicles, from where it
traffics to endosomes and autophagosomes (Couesnon et al., 2009;
Harper et al., 2011, 2016; Restani et al., 2012a). We detected sig-
nificant co-localisation of endocytosed BoNT/A(0) with early endo-
somes and a fraction of BoNT/A(0) remained stable after intoxication,
as has been reported previously for HCC/A (Restani et al., 2012a). In
contrast, HCC/A entry under depolarising conditions induced by high
potassium suggests that the initial level of HCC/A colocalisation with
early endosomes is larger and stable over a longer period of time
(Couesnon et al., 2009; Harper et al., 2011). It should be noted, how-
ever, that potassium depolarisation alters the concentration of orga-
nelles and trafficking of BoNT/A through the endocytic pathway
(Wang, T. et al., 2015).
4.3. BoNT/A(0) is degraded to a stable level by the proteasome
HCC/A has been suggested to traffic to, and be degraded by, lyso-
somes (Harper et al., 2011; Wang, T. et al., 2015). Indeed, we show that
full-length BoNT/A(0) levels decreased during the first 24 h after
treatment, but thereafter remained relatively stable with no significant
further degradation or dissociation occurring over 3 days. Interestingly,
intact BoNT/A has been detected in blood up to 25 days after in-
toxication, suggesting it is remarkably stable (Fagan et al., 2009; Sheth
et al., 2008). Thus, in addition to the well-established stability of the
catalytically active LC, our data suggest there are mechanisms to pro-
tect full-length BoNT/A.
One possible mechanism for the stability and prolonged co-locali-
sation of BoNT/A(0) with early endosomes is that intoxication may
impair endosome maturation. Such behaviour would require a blockade
of the fusion between the phagosome and the lysosome. Indeed, once
endocytosed, some bacteria such as Brucella suis or Salmonella arrest
Fig. 5. BoNT/A(0) is degraded to a stable level by the proteasome.
A) Representative western blot of lysates from DIV14-17 cortical neurons treated with 25 nM BoNT/A(0) for 10 min, after which they were washed and their
corresponding conditioned medium replaced and left for different times. Cells were treated on different days and lysed at the same time. Membranes were probed
with anti-BoNT/A and anti-GAPDH antibodies.
B) Quantification of the data in A. Mean± SEM. ANOVA followed by Tukey post hoc test, ** = p<0.01. N = 4.
C) Representative western blot of samples from DIV14-17 cortical neurons pre-treated for 30 min with vehicle (0.1 % DMSO), 30 μM leupeptin, 5 μM MG132, or a
combination of both, before a 10 min treatment with 25 nM BoNT/A(0) in the continued presence of these compounds. Cells were then washed and replaced in the
corresponding medium containing proteolysis inhibitors for 18 h. Control cells were exposed to 25 nM BoNT/A(0) for 10 min and then lysed immediately. Other
conditions were normalised to these values. Vehicle corresponds to DMSO-treated cells without degradation inhibitors. Membranes were probed with anti-BoNT/A
and anti-GAPDH antibodies.
D) Quantification of the results in C. Mean values± SEM. ANOVA followed by Tukey post hoc test, * = p<0.05, ** = p<0.01. N = 3.
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endosomal maturation to avoid degradation (Kohler and Roy, 2017;
Rajaram et al., 2017; Sun et al., 2013). Moreover, there are intriguing
similarities between these bacteria and BoNT/A – for example, Brucella
suis requires gangliosides to enter cells and is dependent on cholesterol
(Naroeni and Porte, 2002). Alternatively, it is possible that the pro-
longed stability of BoNT/A(0) is due to retention at other locations in
the endolysosomal system. However, further work will be required to
investigate this possibility directly.
It has been reported that in unstimulated neurons a minority of
HCC/A molecules retrogradely traffic in acidic organelles (Restani et al.,
2012a;Wang et al., 2015a, 2015b) and potassium-induced depolarisa-
tion promotes HCC/A trafficking to the lysosome, likely targeting it for
degradation (Wang et al., 2015a, 2015b). In contrast, we show that,
under non-stimulated conditions, intact BoNT/A(0) is predominantly
degraded by the proteasome. This is consistent with the observation
that, once released into the cytosol, the catalytic domain LC/A can be
targeted by the ubiquitin-proteasome system, indicating that LC/A, and
therefore BoNT/A(0), may contain proteasome-targeting ubiquitination
sites (Kuo et al., 2011; Tsai et al., 2017).
4.4. BoNT/A(0) is exocytosed and endocytosed as a full-length toxin in
neurons
Our data suggest that a proportion of BoNT/A(0) can be exocytosed
from treated neurons to enter surrounding neurons. These data raise the
possibility of transcytosis in which BoNT/A(0) enters cells and is sub-
sequently released intact into the medium. It can then be re-en-
docytosed as a full-length toxin. This is consistent with observations
that HCC/A is retrogradely transported in autophagosomes in neurons
(Restani et al., 2012a; Wang et al., 2015a, 2015b) and reports that
BoNT/A effects are found away from the injection site (Antonucci et al.,
2008; Restani et al., 2012b).
In summary, we propose i) BoNT/A exploits various mechanisms to
enter neurons, ii) that, under basal conditions, intact BoNT/A is pri-
marily degraded by the proteasome, iii) that a significant proportion of
BoNT/A remains intact in early endosomes and iv) that some BoNT/
A(0) is exocytosed and re-endocytosed as a full-length toxin. Taken
together, our data characterise the entry and trafficking routes of
BoNT/A and provide important information regarding the behaviour of
the full-length toxin.
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